1. Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration
- Author
-
Manabu Miyata, Nagahisa Yoshimura, Sotaro Ooto, Naoko Ueda-Arakawa, Akio Oishi, Masayuki Hata, Hiroshi Tamura, Kenji Yamashiro, Akitaka Tsujikawa, and Ayako Takahashi
- Subjects
Male ,Vascular Endothelial Growth Factor A ,0301 basic medicine ,medicine.medical_specialty ,Time Factors ,genetic structures ,Fundus Oculi ,Angiogenesis ,Recombinant Fusion Proteins ,Angiogenesis Inhibitors ,Enzyme-Linked Immunosorbent Assay ,Drusen ,Aqueous Humor ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Ranibizumab ,Ophthalmology ,Age related ,medicine ,Humans ,Initial treatment ,Macula Lutea ,Fluorescein Angiography ,Aged ,Retrospective Studies ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Macular degeneration ,medicine.disease ,Fluorescein angiography ,Choroidal Neovascularization ,eye diseases ,Vascular endothelial growth factor ,Vascular endothelial growth factor A ,Receptors, Vascular Endothelial Growth Factor ,030104 developmental biology ,chemistry ,Intravitreal Injections ,Wet Macular Degeneration ,030221 ophthalmology & optometry ,Female ,sense organs ,business ,Tomography, Optical Coherence ,Follow-Up Studies - Abstract
Purpose To investigate the difference in intraocular vascular endothelial growth factor (VEGF) concentration between pachychoroid neovasculopathy and neovascular age-related macular degeneration (nAMD) and its associations with responses to three monthly anti-VEGF injections as an initial treatment for the two conditions. Methods This study included nine eyes with treatment-naive pachychoroid neovasculopathy and 21 eyes with treatment-naive nAMD. Before the initial intravitreal anti-VEGF injection, aqueous humor samples were collected and the concentration of VEGF was measured using enzyme-linked immunosorbent assay. The concentration was compared between the two conditions, and its associations with responses to anti-VEGF therapy were investigated. Results The mean VEGF concentration in pachychoroid neovasculopathy was significantly lower than that in nAMD (63.4 ± 17.8 pg/ml and 89.8 ± 45.0 pg/ml, respectively; P = 0.035). The VEGF concentration was associated with the presence or absence of drusen (β = 0.503, P = 0.004). After anti-VEGF therapy, 6 (66.7%) of 9 eyes with pachychoroid neovasculopathy and 17 (81.0%) of 21 eyes with nAMD achieved dry macula (P = 0.640). Dry macula at 3 months and 12 months was significantly associated with a low VEGF concentration in pachychoroid neovasculopathy (P = 0.013 and P = 0.042, respectively), but not in nAMD (P = 0.108 and P = 0.219). Conclusions The mean VEGF concentration in pachychoroid neovasculopathy was lower than that in nAMD, suggesting that the way in which VEGF is involved in angiogenesis may differ between pachychoroid neovasculopathy and nAMD.
- Published
- 2017
- Full Text
- View/download PDF